Pooja Gokhale, Joshua Caballero, Niying Li, Lorenzo A. Villa Zapata. "Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of EGFR ‐mutated advanced non–small cell lung cancer.." Journal of Clinical Oncology (2026). https://doi.org/10.1200/jco.2026.44.16_suppl.8621